Next-Generation Pharma Company
Focused on advancing a pipeline of potentially best-in-class biologics and RNA therapeutics across areas of unmet need
Pipeline
INHBE (Activin E)
Phase 1
Indication
Obesity
Est. Ph I Initiation
H2 2025
Modality
siRNA
TL1A HLE
Phase I
TL1A-VIAL-HLE has started a phase 1 trial and remains on track to have an interim data readout in H2 2025
Indication
Inflammatory bowel disease (IBD)
Next Data Catalyst
Interim data readout in H2 2025
Modality
Monoclonal antibody
IL-13 x TSLP
Preclinical
Indication
Atopic Dermatitis, Asthma, Chronic Sinusitis
Est. Ph I Initiation
H2 2025
Modality
Half-life extended bi-specific antibody
TMPRSS6
Preclinical
Indication
Polycythemia Vera
Est. Ph I Initiation
Q1 2026
Modality
siRNA
Myostatin (GDF8)
Preclinical
Indication
Obesity
Est. Ph I Initiation
H2 2025
Modality
Half-life extended monoclonal antibody
α4β7 x IL-23
Preclinical
Indication
Inflammatory bowel disease (IBD)
Est. Ph I Initiation
H2 2025
Modality
Bi-specific antibody
Our model is powered by a computational discovery engine and highly automated clinical trials
Computationally Enabled Discovery.
Computationally enabled discovery platform delivers programs with best-in-class, differentiated profiles at-scale.
Automated Clinical Trials.
Leveraging technology to automate clinical trials, enhancing precision and efficiency in drug development.
Recent Updates
Stay updated on recent news and upcoming events.